Prednisolone

Introduction Overview

Generic Name

prednisolone

Brand Name

Flo-Pred
Millipred
Orapred
Pediapred
Veripred 20
Prelone
Hydeltra-T.B.A.
Hydeltrasol
Key-Pred
Cotolone
Predicort
Medicort
Predcor
Bubbli-Pred

Dosage Form

oral liquid
oral suspension
oral syrup
oral tablet
oral disintegrating tablet

Drug Class

Glucocorticoids

Pharmacokinetics

Absorption: Prednisolone is well absorbed following oral administration, with rapid uptake primarily occurring in the gastrointestinal tract, including the stomach and small intestine. Its absorption is generally efficient, allowing for predictable bioavailability; however, food intake may moderately delay absorption without significantly affecting overall bioavailability. The oral liquid and suspension forms facilitate easier absorption and dosing precision in pediatric and patients with swallowing difficulties. Distribution: Once absorbed, prednisolone widely distributes throughout body tissues and fluids, including the central nervous system and ocular tissues. It is approximately 70–90% bound to plasma proteins, predominantly albumin and corticosteroid-binding globulin, which governs its free active concentration. The volume of distribution is moderate, reflecting both intracellular penetration and plasma protein binding, with appreciable distribution to inflammatory sites due to its lipophilic nature. Metabolism: The majority of prednisolone metabolism occurs in the liver via reduction and subsequent conjugation to inactive metabolites, which are primarily sulfated and glucuronidated. Hepatic enzymatic pathways, including cytochrome P450 enzymes, play a critical role, and metabolic clearance can be influenced by hepatic function and coadministered drugs inducing or inhibiting these enzymes. Metabolic conversion rates impact systemic steroid exposure and duration of action. Elimination: Prednisolone and its metabolites are predominantly excreted renally, with approximately 10-15% eliminated unchanged in the urine. The plasma elimination half-life ranges from 2 to 4 hours but the biological half-life extends longer due to receptor-mediated effects. Renal impairment may reduce clearance, necessitating careful monitoring. The compound does not accumulate significantly with repeated dosing when dosed appropriately, although systemic effects may persist due to genomic and non-genomic actions.

Dosage Forms

Available Dosage Forms: Prednisolone is available in several oral formulations to accommodate varied clinical needs. These include oral tablets (standard immediate-release), oral disintegrating tablets designed for rapid dissolution and ease of administration without water, oral suspensions, oral syrups, and oral liquids tailored for pediatric use or those unable to swallow tablets. Specific measured dosing devices are recommended for liquid formulations to ensure dosing accuracy. Dosages for Adults and Adolescents: Dosing regimens are individualized based on the condition treated, severity, and patient response; adult doses typically range from 5 mg to 60 mg daily depending on indication, with tapering schedules common to minimize adrenal suppression. Alternate-day dosing may be employed in chronic therapy to reduce adverse effects. Pediatric dosing utilizes weight-based calculations, often expressed in mg/kg/day, with close monitoring of growth and development. Specific Patient Populations: Dosing adjustments may be necessary in hepatic impairment due to altered metabolism and in renal impairment affecting elimination of metabolites. Special caution and dose modifications are advised during pregnancy and lactation due to limited safety data; benefits versus risks must be assessed. Children require careful monitoring for growth suppression and metabolic side effects. Elderly patients may be more susceptible to steroid-induced osteoporosis and glucose intolerance, necessitating dose consideration.

Mechanism Of Action

Prednisolone functions principally as a synthetic glucocorticoid that mimics endogenous cortisol by binding to cytoplasmic glucocorticoid receptors. Upon ligand binding, the receptor-steroid complex translocates into the nucleus, where it regulates gene expression by binding to glucocorticoid response elements (GREs) in DNA. This modulation results in upregulation of anti-inflammatory proteins and repression of pro-inflammatory gene transcription, including cytokines, chemokines, adhesion molecules, and enzymes such as cyclooxygenase-2 (COX-2). At the cellular level, prednisolone suppresses the migration of leukocytes and inhibits the function of macrophages and lymphocytes, thereby reducing the infiltration and activity of immune cells at sites of inflammation. Additionally, prednisolone inhibits the synthesis and release of inflammatory mediators like prostaglandins and leukotrienes by downregulating phospholipase A2 activity through the induction of lipocortin-1. Clinically, these molecular mechanisms translate into powerful anti-inflammatory and immunosuppressive effects, making prednisolone effective in a wide range of inflammatory, allergic, and autoimmune disorders. Compared to other corticosteroids, prednisolone exhibits a relatively favorable balance of glucocorticoid to mineralocorticoid activity, conferring potent anti-inflammatory properties with lower sodium-retaining effects. Clinical studies have consistently demonstrated prednisolone's efficacy in reducing disease activity and improving symptoms across diverse conditions including arthritis, asthma, inflammatory bowel diseases, and dermatologic disorders. Its rapid onset of action and versatility in dosing formulations support widespread therapeutic use.

Pharmacological Actions

Potent anti-inflammatory agent suppressing multiple components of the inflammatory response.
Immunosuppressive effects via inhibition of leukocyte infiltration and function.
Reduction of capillary permeability to decrease tissue edema and swelling.
Inhibition of pro-inflammatory cytokines and mediators including interleukins, tumor necrosis factor-alpha, and prostaglandins.
Suppression of humoral immune responses and reduction in antibody production.
Modulation of gene expression to increase lipocortin-1, which inhibits phospholipase A2 activity.
Decreases migration of neutrophils and eosinophils to sites of inflammation.
Stabilizes lysosomal membranes, reducing release of proteolytic enzymes.
Exerts metabolic effects including gluconeogenesis and protein catabolism.
Minimal mineralocorticoid effect compared to other corticosteroids, limiting electrolyte imbalances.
Suppresses hypothalamic-pituitary-adrenal (HPA) axis feedback via negative regulation.
Alters distribution and function of T-lymphocytes and macrophages.
Reduces production of nitric oxide and other reactive oxygen species involved in inflammation.
Membrane stabilization effects contributing to reduction in cellular injury.
Decreases expression of adhesion molecules, limiting leukocyte-endothelial interactions.

Therapeutic Or Clinical Uses

Treatment of inflammatory and autoimmune diseases such as rheumatoid arthritis and systemic lupus erythematosus.
Management of allergic reactions including anaphylaxis, rhinitis, and allergic dermatitis.
Control of inflammatory bowel diseases including ulcerative colitis and Crohn's disease.
Treatment of respiratory conditions such as asthma and chronic obstructive pulmonary disease (COPD) exacerbations.
Management of endocrinologic disorders including adrenal insufficiency.
Therapy for dermatologic conditions such as psoriasis and severe eczema.
Use in ophthalmic inflammatory conditions including uveitis.
Treatment of hematologic disorders such as autoimmune hemolytic anemia and thrombocytopenia.
Management of neurological disorders including multiple sclerosis exacerbations.
Control of nephrotic syndrome and other renal inflammations.
Prevention and treatment of graft-versus-host disease post transplantation.
Suppression of immune system in organ transplantation to prevent rejection.
Adjunct therapy in certain malignancies to reduce inflammation and immune responses.
Treatment of congenital adrenal hyperplasia and other endocrine insufficiencies.
Management of acute inflammatory conditions of the ears, nose, and throat.

Side Or Adverse Effects

Fluid retention resulting in peripheral edema.
Hypertension due to mineralocorticoid effects and fluid imbalance.
Hyperglycemia and potential induction or worsening of diabetes mellitus.
Increased susceptibility to infections including reactivation of latent infections.
Osteoporosis with prolonged use due to decreased bone formation and increased resorption.
Gastrointestinal disturbances including stomach discomfort, gastritis, and increased risk of peptic ulcers.
Central nervous system effects such as mood changes, psychosis, depression, or cognitive impairment.
Muscle weakness and steroid myopathy.
Growth suppression in pediatric patients.
Skin changes including thinning, bruising, delayed wound healing, and acne.
Electrolyte imbalances such as hypokalemia and sodium retention.
Increased intraocular pressure with risk of glaucoma and cataracts.
Menstrual irregularities and reproductive hormone disturbances.
Weight gain and redistribution of body fat leading to 'moon face' and truncal obesity.
Adrenal suppression and withdrawal symptoms if stopped abruptly.

Precautions

Avoid use in patients with systemic fungal infections due to immunosuppression.
Use with caution in patients with active or latent tuberculosis.
Monitor blood glucose regularly in diabetic patients or those at risk of hyperglycemia.
Screen and monitor for osteoporosis, especially in elderly patients and long-term therapy.
Caution in patients with hypertension or cardiac disease due to fluid retention.
Adjust dosing during periods of physiological stress such as surgery or severe illness.
Avoid live vaccines during therapy to prevent vaccine-related infections.
Careful tapering required to prevent adrenal insufficiency upon discontinuation.
Monitor psychological status due to risk of mood and behavior changes.
Use cautiously in patients with peptic ulcer disease or gastrointestinal bleeding history.
Assess for history of adrenal suppression or HPA axis dysfunction.
Monitor electrolyte levels during prolonged therapy to detect imbalances.
Caution in patients with hepatic impairment due to altered metabolism.
Evaluate bone density periodically to mitigate risk of steroid-induced osteoporosis.
Consider potential drug-drug interactions that may alter prednisolone metabolism or effects.

Warnings

Do not use in patients with systemic fungal infections.
Prednisolone can mask signs of infection and increase susceptibility to new infections.
Abrupt discontinuation can result in adrenal crisis; taper dose gradually.
Use caution in patients with active herpes simplex infections of the eye.
Risk of serious adverse psychiatric reactions including severe depression and psychosis.
May cause increased intraocular pressure leading to glaucoma.
Potential for growth suppression in pediatric patients on long-term therapy.
Avoid live vaccines during and shortly after therapy to prevent vaccine complications.
Can cause fluid retention leading to exacerbation of heart failure.
Risk of gastrointestinal perforation especially in patients with diverticulitis or peptic ulcer.
May worsen hypertension, diabetes mellitus, and mood disorders.
Possibility of muscle weakness and myopathy with prolonged high-dose therapy.
Monitor for symptoms of Cushing's syndrome with chronic use.
Use cautiously in pregnancy; potential risks and benefits must be considered.
Notify medical personnel of corticosteroid use prior to surgery or emergency care.

Contraindication

Known hypersensitivity to prednisolone or any component of the formulation.
Systemic fungal infections due to immunosuppressive risk.
Administration of live or live-attenuated vaccines during therapy.
Patients with untreated bacterial infections unless on appropriate antimicrobial therapy.
Certain viral infections such as herpes simplex of the eye without adequate treatment.
Avoid in patients with history of hypersensitivity reactions to glucocorticoids.
Severe psychosis or psychiatric disorders unless benefits outweigh risks.
Use cautioned or avoided in systemic varicella infection due to risk of dissemination.
Contraindicated in patients with active, severe infections where immune suppression is hazardous.
Do not initiate in individuals with gastrointestinal perforation risk when benefits do not exceed risks.

Drug Interactions

Enzyme-inducing drugs such as rifampin, phenytoin, phenobarbital may reduce prednisolone efficacy by increasing metabolism.
Concurrent use with nonsteroidal anti-inflammatory drugs (NSAIDs) may increase risk of gastrointestinal ulceration and bleeding.
Potassium-depleting diuretics may exacerbate hypokalemia caused by corticosteroids.
Live vaccines may have reduced efficacy and increased risk of infection during prednisolone use.
Drugs that inhibit cytochrome P450 enzymes, like ketoconazole, may increase prednisolone plasma levels and toxicity.
Co-administration with anticoagulants may alter coagulation parameters and require monitoring.
Combination with antidiabetic agents may necessitate dose adjustments due to hyperglycemic effects.
Prednisolone may reduce the efficacy of vaccines and impair immune responses.
Concomitant use with immunosuppressants or cytotoxic drugs can increase infection risk.
Interactions with estrogen-containing contraceptives can decrease prednisolone clearance.
May increase the clearance of salicylates, reducing their efficacy.
Potential additive effects with other CNS-active drugs including anxiolytics and antidepressants.
Concurrent use with digoxin requires monitoring due to risk of arrhythmias from hypokalemia.
Interactions with certain antihypertensives may reduce blood pressure control.
Coadministration with CYP3A4 inhibitors or inducers requires vigilance for altered prednisolone levels.

Preparations Of The Drug

Prednisolone oral tablets available in multiple strengths to facilitate flexible dosing.
Oral disintegrating tablets designed for rapid onset and ease of administration without water.
Prednisolone oral suspension formulated for pediatric use with measurable dosing devices.
Oral syrup formulations with palatable flavor profiles to improve pediatric adherence.
Prednisolone sodium phosphate oral solutions as water-soluble salt forms.
Preservative-free formulations available for patients with sensitivities.
Multi-dose vials with appropriate storage recommendations to maintain stability.
Available in both immediate and short-acting release preparations for clinical flexibility.
Compounded formulations may be prepared for dose customization in special populations.
FDA-approved packages include dosing syringes or cups for liquid formulations.
Some brands may include anti-oxidants or flavoring agents tailored to patient populations.
Packaging for disintegrating tablets includes blister packs for moisture protection.
Standard storage conditions at room temperature, protected from moisture and heat.
Specific formulations designed for use in infants, children, and adults.
Certain topical and ophthalmic prednisolone preparations available but distinct from oral forms.